Shopping Cart
- Remove All
Your shopping cart is currently empty
Lumasiran sodium
Catalog No. T39274Cas No. 1834612-06-4
Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, targets glycolate oxidase to reduce hepatic oxalate production and urinary oxalate excretion, showing promise in addressing the underlying cause of progressive kidney failure in individuals with primary hyperoxaluria type 1 (PH1).
Lumasiran sodium
Catalog No. T39274Cas No. 1834612-06-4
Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, targets glycolate oxidase to reduce hepatic oxalate production and urinary oxalate excretion, showing promise in addressing the underlying cause of progressive kidney failure in individuals with primary hyperoxaluria type 1 (PH1).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $1,520 | Backorder |
Bulk & Custom
Add to Cart
Questions
View MoreContact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, targets glycolate oxidase to reduce hepatic oxalate production and urinary oxalate excretion, showing promise in addressing the underlying cause of progressive kidney failure in individuals with primary hyperoxaluria type 1 (PH1). |
| In vitro | Lumasiran sodium is utilized in the study of Primary Hyperoxaluria Type 1 (PH1). It functions by silencing the gene responsible for glycolate oxidase production, subsequently reducing glycolate oxidase levels. This inhibition blocks oxalate synthesis, the harmful metabolite linked to PH1's clinical symptoms[1]. |
| In vivo | Lumasiran sodium is a liver-targeted therapeutic agent administered subcutaneously, functioning through RNA interference (RNAi) [2]. |
| Cas No. | 1834612-06-4 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Lumasiran sodium | purchase Lumasiran sodium | Lumasiran sodium cost | order Lumasiran sodium | Lumasiran sodium chemical structure | Lumasiran sodium in vivo | Lumasiran sodium in vitro
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.